Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Carl Akin

Cardiovascular Disease Independence, MO Medical Doctor

NPI 1871598052 CMS profile 312239

19550 E 39Th St S, Suite 220, Independence, MO 64057

Open in the dashboard

General payments

$2,998

195 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Carl Akin of Independence, MO is reported in the CMS Open Payments database as having received $2,998 across 195 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 58th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $29 2
2022 General $498 28
2021 General $773 49
2020 General $536 39
2019 General $1,162 77

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carl Akin
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Carl Akin were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Carl Akin Cardiovascular Disease median Middle half National median
2019 $1,162 $450 $127–$1,392 $163
2020 $536 $242 $77–$751 $114
2021 $773 $335 $101–$1,037 $132
2022 $498 $395 $121–$1,211 $149
2023 $29 $443 $136–$1,283 $160
2024 $0 $450 $136–$1,323 $164
2025 $0 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Janssen Pharmaceuticals, Inc $654 38 payments
  2. Amgen Inc. $577 42 payments
  3. Sanofi-Aventis U.S. LLC $266 20 payments
  4. Amarin Pharma Inc. $189 11 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $184 12 payments
  6. E.R. Squibb & Sons, L.L.C. $173 13 payments
  7. Pfizer Inc. $134 9 payments
  8. Boston Scientific Corporation $132 7 payments
  9. Novartis Pharmaceuticals Corporation $128 9 payments
  10. AstraZeneca Pharmaceuticals LP $111 7 payments
  11. Other $449 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $2,928 191 payments
  2. Education $50 3 payments
  3. Consulting Fee $20 1 payment
Products named General payments · program years 2019–2023
  1. XARELTO $654 38 payments
  2. Repatha $577 42 payments
  3. Corlanor $336 26 payments
  4. JARDIANCE $184 12 payments
  5. ELIQUIS Cardiovascular $173 13 payments
  6. ELIQUIS Cardiovascular;Metabolic Disease $121 8 payments
  7. ENTRESTO $103 7 payments
  8. Vascepa Cardiovascular $98 6 payments
  9. BRILINTA $97 6 payments
  10. Vascepa Hypertriglyceridemia $92 5 payments
  11. Other $1,021 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

195 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record